Chamber and committees

Scotland’s screening policy relies on recommendations from the UK National Screening Committee (UK NSC), an independent scientific body that provides advice on screening policy to all four UK nations. To date, the UK NSC has not recommended Spinal Muscular Atrophy (SMA) screening through the existing newborn blood spot test, and has stated it requires further evidence before a decision can be made.

The UK NSC continues to monitor and review the rapidly developing evidence base regarding SMA screening. Most recently, in November 2024, the interim results of a new modelling study into SMA screening for the UK context were presented at a workshop to stakeholders. The findings of this study, in conjunction with the proposed In Service Evaluation of SMA screening in some areas of England, will inform the UK NSC’s considerations regarding whether SMA screening should be recommended.

The UK NSC updates on significant developments regarding potential and existing screening programmes on their blog. This can be found at UK National Screening Committee – News and updates from the UK National Screening Committee

The Scottish Government does not share this view.

Within the Scottish Government, funding of Health and Care Research comes under the remit of the Chief Scientist Office (CSO).

CSO funds research projects via its Translational Clinical Studies (TCS) Committee and the Health Improvement, Protection and Services Research (HIPS) Committee

https://www.cso.scot.nhs.uk/grant-funding/response-mode-funding-schemes/

CSO funds capacity building research via its Fellowship Funding programmes

https://www.cso.scot.nhs.uk/fellowship-funding/

Research funding is not allocated to any particular condition and CSO funds research across the clinical spectrum. All applications go through a process of independent expert review to allow funding decisions to be made. Applications on Brain Tumours are welcomed and CSO's role is well known across the Health and Care research community in Scotland

In 2023-24 the following funding was awarded specifically for research in Brain Cancer

TCS/23/18 - Assessment of Brain Tumours with Dynamic T2* and Lactate MR under Oxygen Challenge to Evaluate Aerobic and Anaerobic Metabolic Status of Gliomas

£299,918

Tessa Jowell Fellowship in Neuro-oncology

£44,237

In addition, CSO provides infrastructure funding to support the delivery of clinical studies in the NHS in Scotland. In 2023-24 the cancer-specific component of this infrastructure funding was £1,112,434. This figure includes funding for the NHS Research Scotland Cancer Research Network and the CSO component of funding for the Experimental Cancer Medicine Centres in Edinburgh and Glasgow (co-funded 50:50 with Cancer Research UK). The purpose of this funding is to support the delivery of early and later phase cancer clinical studies, including in Brain Tumours.

The Scottish Government would advise that the question does not take into account section 8(4)(b) of the Planning (Listed Buildings and Conservation Areas) (Scotland) Act 1997. While the summary conviction can carry a fine up to £50,000 the legislation also allows for a fine on conviction on indictment to which no maximum is provided.

There is no lack of emergency access to any specialty over winter.

Our planning for this winter builds on the effective measures which have supported our health and social care services through previous years. However, we stand ready to take additional measures, if necessary, with all specialties, including urology.

We have developed our winter plan with input from the whole Health and Social Care system which brings together best practice and improvement work which we know works from lessons learned in previous winters, to ensure that the most appropriate care is received in the right place and at the right time.

Waits often occur due to a wait for an inpatient bed – in these circumstances patients will have been assessed by emergency department staff and their condition will be monitored while they remain in the department.

NHS Greater Glasgow and Clyde is maximising theatre access for all surgical specialties. The Health Board are also running additional waiting list sessions targeted at various surgical specialties, including urology.

NHS Greater Glasgow & Clyde North Sector, has established a one-stop urology, diagnostic and treatment service which provides earlier diagnosis for patients.

Significant additional activity is already underway following the allocation of £30 million funding to target reductions to the national backlogs that built up throughout the pandemic. This funding is being targeted at a series of national and local plans to reduce backlogs by maximising the use of local and national resources across Scotland. It is estimated this will help boards across the country deliver around 12,000 additional inpatient and day-case procedures, over 40,000 extra diagnostic procedures and around 12,000 new outpatient appointments.

This is an operational matter for Scottish Enterprise. I have asked their Chief Executive, Adrian Gillespie, to contact you directly with a response.

This is an operational matter for Scottish Enterprise. I have asked their Chief Executive, Adrian Gillespie, to contact you directly with a response.

In line with Ministerial priorities in the current challenging fiscal context, officials are always considering options and opportunities for Scottish Government's estate that make the best possible use of our existing assets and deliver value for money. The Scottish Minister’s leasehold interest at 5 Atlantic Quay, Glasgow is being considered as part of that strategic estate work. We cannot comment further at this time due to the commercial sensitivities involved.

The Scottish Government is aware that, since April 2024, there has been ongoing supply issues with the availability of naloxegol (Moventig®) tablets. On 25 April 2024, the Scottish Government issued a Medicines Supply Alert Notice to NHS Scotland on the availability of naloxegol (Moventig®) tablets. Medicines Supply Alert Notices are circulated to Medical Directors and Directors of Pharmacy across all Health Boards including national Health Boards (such as NHS National Services Scotland) for onward dissemination to healthcare professionals. Community Pharmacy Scotland also receive a copy of the Medicines Supply Alert Notices for onward dissemination across their network.